कंपनी का अवलोकन
Akebia Therapeutics, Inc. is a biopharmaceutical entity dedicated to the research, development, and commercialization of therapeutic solutions specifically designed for patients suffering from kidney diseases. The company operates within the Healthcare sector, functioning as a Drug Manufacturer within the Specialty & Generic sub-industry, a classification that denotes its focus on specialized pharmaceutical compounds rather than mass-market generics. The organization employs a workforce of 194 individuals and holds a market capitalization of $377.71M, with annual revenue reported at $236.20M. These valuation and revenue figures indicate that the company maintains a mid-market capitalization profile, suggesting it is an established player with significant operational scale but one that has not yet achieved the massive valuation multiples typically associated with large-cap pharmaceutical giants.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $236.20M alongside a net income of $-5,345,000, while generating an EBITDA of $27.27M. The substantial gap between positive revenue and negative net income reveals a cost structure characterized by significant non-operating expenses or interest charges that erode bottom-line profitability despite strong top-line sales. Despite the reported net loss, the firm demonstrates robust financial flexibility by generating $68.61M in free cash flow, a metric that suggests strong operational efficiency and the capacity to fund operations without relying heavily on external financing. The margins further illustrate this complex financial picture: a gross margin of 82.9% indicates highly efficient production and pricing power, whereas an operating margin of -10.5% and a profit margin of -2.3% signal that overhead costs and other expenses are currently exceeding operating profits. On the balance sheet, the company holds $184.84M in cash against $198.78M in debt, resulting in a debt-to-equity ratio of 609.57, which implies a highly leveraged financial position where debt significantly outweighs shareholder equity. However, the current ratio of 1.55 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting adequate short-term liquidity despite the leverage. Furthermore, the Return on Equity is listed as N/A due to the lack of profitability, while the Return on Assets stands at 5.4%, revealing that the company is generating a modest positive return on its total asset base even while reporting a net loss.
मूल्यांकन आकलन
Valuation metrics for Akebia Therapeutics present a unique profile given the company's earnings situation, with a trailing P/E ratio of N/A and a forward P/E of -14.84. The existence of a negative forward P/E implies that analysts project the company will not be profitable in the near term, causing the traditional earnings-based multiple to invert and lose conventional interpretive value. The price-to-book ratio is recorded at 11.46, which indicates that the market values the company at a significant premium over its tangible book value, reflecting high expectations for future drug approvals or commercial success. Alternative valuation measures provide additional context, with a price-to-sales ratio of 1.60 and an EV/EBITDA of 14.36, suggesting that investors are pricing the stock based on revenue generation and earnings before interest, taxes, and depreciation rather than current net income. Regarding price action, the 52-week high is $4.08 and the 52-week low is $1.14, meaning the current price sits within this established trading range but is positioned closer to the upper end relative to the recent low. The beta value is 0.37, indicating that the stock exhibits low volatility and tends to move less aggressively than the broader market index, offering a more stable price profile for risk-averse portfolios compared to high-beta biotech peers.
Growth & Income
The company has demonstrated notable top-line expansion with a revenue growth rate of 23.9% year-over-year, whereas the earnings growth rate is N/A due to the current unprofitable status. This divergence implies that the company is prioritizing market share expansion and revenue scaling over immediate profit generation, a common strategy in the early-to-mid stages of biopharmaceutical development. As a non-dividend payer, Akebia Therapeutics reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all earnings to reinvest into research and development rather than distributing income to shareholders. The overall growth and income profile is defined by aggressive revenue expansion coupled with a complete absence of dividend income, creating a capital appreciation-focused investment thesis reliant on future profitability milestones.